Abstract 809P
Background
Gynecological cancer may have severe implications in women, as these diagnoses are likely to have negative consequences on mental health and socioeconomic status. We used the Swedish national population and healthcare registries to assess the association between diagnosis of endometrial or cervical cancer and risk for mental disorders, as well as for socioeconomic consequences.
Methods
We performed a population-based nested case-control study based on more than 5 million women in Sweden, identifying 6,060 cases of cervical cancer and 17,932 cases of endometrial cancer diagnosed during 2006-2018. Each cancer case was matched with five healthy controls randomly selected from the population born in the same year. Data on comprehensive set of mental disorders, loss of employment, early retirement or need for sickness benefit, family receipt of financial assistance, decrease of individual income and family income before versus after cancer diagnosis were retrieved from population registries. Conditional logistic regression and stratified Cox regression models with confounder adjustment were conducted to estimate odds ratios (OR) and 95% confidence intervals (CI).
Results
Mental disorders were prevalent to a moderate degree before diagnosis among cervical cancer patients, but less prevalent in endometrial cancer patients. After cancer diagnosis, incident (i.e. new) mental disorders started emerging within the first 2-5 years and then persisted. The risk was higher following cervical cancer (OR=3.7, 95% CI=3.5-4.1) as compared to endometrial cancer (OR=2.1, 95% CI=2.0-2.2). Before cancer diagnosis, economic status was comparable between cancer patients and control women. Financial assistance and income decrease rose early after diagnosis, with 1.2-2.1 times increased risk among cancer patients. Unemployment, early retirement and need for sickness benefit doubled from two years after cancer diagnosis and onwards. Impact was more pronounced among cervical cancer patients.
Conclusions
Women with cervical cancer and endometrial cancer are affected mentally and financially after the cancer diagnosis. The impact is more pronounced among cervical cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
MSD Sweden.
Disclosure
J. Wang, K. Sundström: Financial Interests, Institutional, Research Funding: MSD. A.L. Feldman: Financial Interests, Institutional, Other: Has been part of research collaborations within partnership programs between Karolinska Institutet and respectively MSD Sweden/Merck and Janssen Pharmaceutica NV. G. Bencina, M. Andersson, S. Salomonsson: Financial Interests, Personal, Full or part-time Employment: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11